Denosumab biosimilar - Shandong Boan Biotechnology

Drug Profile

Denosumab biosimilar - Shandong Boan Biotechnology

Alternative Names: LY 06006

Latest Information Update: 22 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Shandong Boan Biotechnology
  • Developer Luye Pharma Group; Shandong Boan Biotechnology
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies; Osteoporosis therapies
  • Mechanism of Action RANK ligand inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Postmenopausal osteoporosis

Most Recent Events

  • 10 Jan 2018 Phase-I clinical trials in Postmenopausal osteoporosis (In volunteers) in China (Parenteral) (NCT03427853)
  • 04 Aug 2017 Luye Pharma Group acquires denosumab biosimilar from Shandong Bo’an Biotechnology
  • 04 Aug 2017 Preclinical trials in Postmenopausal osteoporosis in China (Parenteral) before August 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top